Around the Practice: Adjuvant Therapy in NSCLC

A panel of experts review two patient cases to elucidate data in the adjuvant setting of non–small cell lung cancer.

EP. 1: Biomarker Testing Practices in Non-Small Cell Lung Cancer

April 29th 2022

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

EP. 2: Factors in Selecting Therapy for Non-Small Cell Lung Cancer

April 29th 2022

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

EP. 3: Patient Profile 1: Stage IIB NSCLC With High PD-L1 Expression

May 6th 2022

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

EP. 4: Role of Immunotherapy in Newly Diagnosed NSCLC

May 6th 2022

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

EP. 5: CheckMate-816: Neoadjuvant Chemoimmunotherapy for NSCLC

May 13th 2022

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

EP. 6: IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC

May 13th 2022

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

EP. 7: NSCLC: Selecting Therapy Based on PD-L1 Status and Staging

May 20th 2022

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

EP. 8: Patient Profile 2: EGFR Exon 19 Deletion–Positive NSCLC

May 20th 2022

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.